- Recombinant protein vaccines, developed using engineered DNA to produce immunogenic proteins, are gaining prominence due to their safety profile, scalability in production, and ability to target specific antigens without using live pathogens. They are increasingly vital in immunization programs targeting diseases such as hepatitis B, HPV, and COVID-19
- The rising demand for recombinant protein vaccines is driven by growing global vaccination initiatives, advancements in recombinant DNA technology, and an increasing preference for subunit vaccines due to fewer side effects and improved stability
- North America dominated the recombinant protein vaccines market with the largest revenue share of 41.9% in 2024, attributed to robust healthcare infrastructure, early adoption of advanced biotechnologies, and a high rate of immunization coverage. The U.S. leads the region with strong R&D investments and government support for vaccine development and procurement
- Asia-Pacific is projected to be the fastest growing region in the recombinant protein vaccines market during the forecast period (2025–2032), driven by expanding healthcare access, rising investments in biopharmaceuticals, and large-scale government-led immunization programs across countries such as China, India, and Japan
- The Bacterial Cells Culture segment dominated the recombinant protein vaccines market with the largest revenue share of 61.3% in 2024, owing to its cost-effective production process, rapid growth rate, and scalability for high-yield recombinant protein expression. This culture system is widely used for producing non-glycosylated proteins and bacterial-targeted vaccines. Its widespread application across R&D and commercial platforms strengthens its market leadership
